Andere Sprachen BioNxt Solutions Inc. Börse Stuttgart

Aktien

A3D1K3

CA0909741062

BXT

Pharmazeutika

Verzögert Börse Stuttgart Andere Börsenplätze 18:18:02 11.06.2026			% 5 Tage	Veränd. 1. Jan.
0,2200 ^EUR	-0,45 %		-1,78 %	-46,62 %

29.05.	BioNxt Solutions Inc. veröffentlicht Ergebniszahlen für das erste Quartal zum 31. März 2026	CI
29.04.	BioNxt Solutions Inc. veröffentlicht Ergebniszahlen für das am 31. Dezember 2025 endende Geschäftsjahr	CI

Andere Sprachen

00:32	BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants
29.05.	BioNxt Solutions Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
19.05.	BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development
29.04.	BioNxt Solutions Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
29.04.	BioNxt Solutions Inc. Auditor Raises 'Going Concern' Doubt
28.04.	BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum
14.04.	BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
07.04.	BioNxt Solutions Registers Its ODF Platform With the European Patent Office
07.04.	BioNxt : Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
30.03.	BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
24.03.	BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
17.03.	BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
17.02.	BioNxt : Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
21.01.	BioNxt Solutions Inc. Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery
20.01.	Bionxt Solutions Inc. Announce Significant Progress in Its Mission to Address One of the Most Overlooked Barriers in Medicine
20.01.	Bionxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual Odf
17.12.	BioNxt Solutions Inc. Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
17.12.	BioNxt : Over 40% of Adults Struggle to Swallow Pills – BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
09.12.	BioNxt : Advances “Melt in Your Mouth” Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
28.11.	BioNxt Solutions Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
04.11.	Bionxt Solutions Inc. Launches 15-Day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
04.11.	Bionxt Reports Readiness to Grant Patent Notification from the Eurasian Patent Organization
14.10.25	CSE Bulletin: MOC Eligibility Update
13.10.25	BioNxt : Completes “Fast-Track” US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
10.10.25	BioNxt Solutions Inc. Advances Semaglutide Oral Dissolvable Film Program with Successful Proof-of-Concept and Prototype Development